Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Self-reported health status and the associated risk of mortality in heart failure: The DANISH trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections is Dependent on Streptococcal Species

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). The aim of the study was to examine the safety and tolerability of fulacimstat in patients with LVD after remote MI. A multicenter, multinational randomized, placebo-controlled study was performed in clinically stable patients (40-79 years of age, left ventricular ejection fraction ≤ 45% because of MI in medical history) who were on stable evidence-based standard-of-care therapies for LVD post-MI including an angiotensin converting enzyme inhibitor or angiotensin receptor blocker at doses of at least half the recommended target dose. Patients were treated for 2 weeks with either placebo (n = 12) or 4 different doses of fulacimstat (5 mg twice daily, n = 9; 10 mg twice daily, n = 9; 25 mg twice daily, n = 10; 50 mg once daily, n = 9). Fulacimstat was safe and well tolerated at all examined doses. There were no clinically relevant effects on vital signs or potassium levels compared with placebo treatment. Mean plasma concentrations of fulacimstat increased with the administered dose and reached exposures predicted to be therapeutically active. The safety profile and the absence of effects on blood pressure or heart rate in a chronic patient population having similar comorbidities and receiving similar comedication as patients after acute MI support future clinical trials with fulacimstat in patients after acute MI.

TidsskriftClinical Pharmacology in Drug Development
Udgave nummer7
Sider (fra-til)942-951
Antal sider10
StatusUdgivet - 2019

ID: 56241171